# Aprea Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aprea-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aprea.com
- Total disclosed funding: $112M
- Latest round: Series C (Feb 27, 2019)
- Investors on record: 8

## About

Aprea Therapeutics, Inc., based in the US, focuses on the development of innovative therapeutics targeting DNA Damage Response (DDR) mechanisms to treat various cancer types, improving treatment efficacy with minimized side effects.Founded in 2003 and headquartered in Boston, US, Aprea Therapeutics specializes in cancer therapeutics. The company has raised a total of USD 5.51 mn through multiple funding rounds, with the most recent being a Private Placement/Follow on in February 2023. The company’s CEO is Oren Gilad, and it was founded by Vladimir Bykov. Aprea has engaged in 9 deals, with its last deal occurring on October 2, 2019.Aprea Therapeutics specializes in developing innovative DNA Damage Response (DDR) targeted cancer therapeutics aimed at addressing specific genetic mutations associated with various cancer types. The company's core product offerings include small molecule inhibitors designed to enhance the efficacy of cancer treatments while minimizing toxicity to healthy tissues. These therapeutics are crafted to widen the therapeutic window, focusing on the precise matching of treatments to patients based on their unique cancer profiles. Aprea’s product pipeline targets multiple genetic mutations to improve treatment outcomes, thereby catering to a diverse client base that includes healthcare providers and oncology specialists in regions such as North America and Europe. The end users of Aprea’s therapies are primarily oncology patients seeking effective treatments for their specific cancer conditions, with the aim of significantly altering their treatment journey.In 2023, Aprea Therapeutics reported revenue of USD 583,231. The company also faced an EBITDA loss of USD 15,464,911 for the same year. Aprea generates revenue through collaborations and partnerships with healthcare institutions and pharmaceutical companies, focusing on B2B transactions. The structure of these partnerships may involve licensing agreements and joint ventures, enabling the company to leverage external expertise while advancing its therapeutic pipeline. Revenue may also be generated through clinical trial collaborations and research funding, allowing Aprea to bring its products to market effectively. The company’s flagship product offerings are positioned to attract significant interest from healthcare providers, given their targeted approach to treatment.Aprea Therapeutics aims to leverage its recent funding from the Private Placement in February 2023 to further develop its clinical drug ATRN-119, pre-clinical drug ATRN-W1051, and support general corporate purposes. The company is also looking to expand its market reach, particularly in North America and Europe, by launching new products tailored to specific genetic mutations in cancer. The funding will facilitate ongoing clinical trials and enhance research capabilities, thereby bolstering Aprea's position in the oncology market.

## Funding rounds

- Series C, Feb 27, 2019, $5.7M — Janus Henderson Investors
- Series C, Nov 30, 2018, $57M — Versant Ventures, HealthCap, 5AM Ventures, Karolinska Development, Redmile Group, Sectoral Asset Management, Rock Springs Capital
- Series B, Mar 9, 2016, $50M — Versant Ventures, 5AM Ventures, Sectoral Asset Management, HealthCap

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series C
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series B, Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B, Series C
- HealthCap — Series B, Series C
- Karolinska Development — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- Rock Springs Capital — Series C
- Janus Henderson Investors — Series C